Pfizer Inc.-Product Pipeline Review-2016

Pfizer Inc.-Product Pipeline Review-2016


  • Products Id :- GMDHC07989CDB
  • |
  • Pages: 419
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Global Markets Direct's, 'Pfizer Inc.-Product Pipeline Review-2016', provides an overview of the Pfizer Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Pfizer Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Pfizer Inc.

The report provides overview of Pfizer Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Pfizer Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Pfizer Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

Evaluate Pfizer Inc.'s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Pfizer Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Pfizer Inc.'s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 7

Pfizer Inc. Snapshot 8

Pfizer Inc. Overview 8

Key Information 8

Key Facts 8

Pfizer Inc.-Research and Development Overview 9

Key Therapeutic Areas 9

Pfizer Inc.-Pipeline Review 21

Pipeline Products by Stage of Development 21

Pipeline Products-Monotherapy 22

Pipeline Products-Combination Treatment Modalities 23

Pipeline Products-Partnered Products 24

Pipeline Products-Out-Licensed Products 27

Pfizer Inc.-Pipeline Products Glance 31

Pfizer Inc.-Late Stage Pipeline Products 31

Pfizer Inc.-Clinical Stage Pipeline Products 35

Pfizer Inc.-Early Stage Pipeline Products 39

Pfizer Inc.-Drug Profiles 42

(naltrexone hydrochloride + oxycodone hydrochloride) ER 42

crizotinib 44

palbociclib 48

tofacitinib 52

epoetin zeta 56

gemtuzumab ozogamicin 58

tafamidis meglumine 59

(ertugliflozin + metformin hydrochloride) 61

(ertugliflozin + sitagliptin phosphate) 62

adalimumab biosimilar 63

axitinib 64

bevacizumab biosimilar 68

bococizumab 69

bosutinib 70

celecoxib 73

dacomitinib 75

ertugliflozin 78

gosogliptin 80

infliximab biosimilar 81

inotuzumab ozogamicin 82

meningococcal [serotype B] vaccine 84

pregabalin 86

pregabalin CR 88

rituximab biosimilar 89

rivipansel sodium 90

sildenafil citrate 93

sunitinib malate 95

tanezumab 99

trastuzumab biosimilar 102

ziprasidone mesylate 103

ascrinvacumab 104

Dekavil 105

domagrozumab 106

fosdagrocorat 107

gedatolisib 108

glasdegib 110

lorlatinib 112

Nimenrix 114

nirogacestat 117

PF-00489791 119

PF-00547659 120

PF-02545920 122

PF-04236921 124

PF-04457845 125

PF-05089771 126

PF-06290510 128

PF-06291874 130

PF-06425090 131

PF-06838435 132

ponezumab 133

temsirolimus 135

agatolimod sodium 137

pegfilgrastim 140

PF-06747775 141

filgrastim 142

HIV vaccine 143

PF-04136309 144

PF-04447943 146

PF-04518600 147

PF-04958242 148

PF-05082566 150

PF-05206388 152

PF-05230907 153

PF-05251749 154

PF-05402536 155

PF-06266047 156

PF-06273340 157

PF-06282999 158

PF-06293620 159

PF-06342674 160

PF-06412562 161

PF-06413367 162

PF-06427878 163

PF-06444752 164

PF-06444753 166

PF-06480605 167

PF-06647020 168

PF-06647263 169

PF-06648671 170

PF-06649751 171

PF-06650808 172

PF-06650833 173

PF-06651600 174

PF-06664178 175

PF-06669571 176

PF-06678552 177

PF-06700841 178

PF-06741086 179

PF-06751979 180

PF-06753512 181

PF-06755990 182

PF-06755992 183

PF-06801591 184

PF-06815345 185

Biologics for Undisclosed Indication 186

Biologics to Target PCSK-9 for Hypercholesterolemia 187

CE-355621 188

Drugs for Duchenne Muscular Dystrophy 189

GIBH-1008 190

GIBH-1010 191

GIBH-1018 192

GL-2045 193

HSD-621 194

J-17 195

Monoclonal Antibodies for Solid Tumor 196

MOR-8457 197

NIC7-DT 198

PD-0360324 199

PF-01247324 200

PF-06380101 201

PF-06447475 202

PF-06671008 203

PF-1355 204

PF-3845 205

PF-4989216 206

PF-5006739 207

PNU-120596 208

Proteins to Agonize MC4R for Obesity 209

RBT-301 210

Small Molecule 1 for Solid Tumors 211

Small Molecule to Antagonize Tie-2 Receptor for Solid Tumor 212

Small Molecule to Inhibit IDO-1 for Oncology 213

Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections 214

Small Molecule to Inhibit TDO-2 for Oncology 215

Small Molecule to Modulate Androgen Receptor for Muscle Disorders 216

Small Molecules to Activate CFTR for Cystic Fibrosis 217

Small Molecules to Inhibit Mps1 for Breast Cancer 218

Small Molecules to Inhibit NMT for Malaria 219

Small Molecules to Inhibit PDE2 for Osteoarthritis Pain 220

Vaccine 2 for Undisclosed Indication 221

Monoclonal Antibody Conjugates for Oncology 222

PF-00190434 223

PF-04445597 224

PF-46396 225

PPD-1 226

Small Molecule to Agonize LXR for Inflammation 227

Small Molecule to Agonize Melanocortin Receptor 3 for Rheumatoid Arthritis and Inflammation 228

Small Molecule to Antagonize Ghrelin Receptor for Alcoholism 229

Small Molecule to Antagonize Melanocortin Receptor 2 for Cushing's Disease and Congenital Adrenal Hyperplasia 230

Small Molecule to Inhibit Acetyl-CoA Carboxylase for Metabolic Disorders 231

Small Molecule to Inhibit EZH2 for Oncology 232

Small Molecule to Inhibit MMP13 for Osteoarthritis 233

Small Molecule to Inhibit NS5A for HCV 234

Small Molecule to Inhibit PI3K Alpha and mTOR for Oncology 235

Small Molecule to Inhibit Pin1 for Oncology 236

Small Molecule to Target AGTR1 and PPAR gamma for Hypertension and Metabolic Syndrome 237

Small Molecules for Inflammatory and Orphan Diseases 238

Small Molecules for Obesity and Diabetes 239

Small Molecules for Ulcerative Colitis and Crohn's Disease 240

Small Molecules to Agonize A1 Adenosine Receptor 241

Small Molecules to Agonize ADRB2 and Antagonize CHRM3 for COPD 242

Pfizer Inc.-Pipeline Analysis 243

Pfizer Inc.-Pipeline Products by Target 243

Pfizer Inc.-Pipeline Products by Route of Administration 252

Pfizer Inc.-Pipeline Products by Molecule Type 253

Pfizer Inc.-Pipeline Products by Mechanism of Action 254

Pfizer Inc.-Recent Pipeline Updates 262

Pfizer Inc.-Dormant Projects 342

Pfizer Inc.-Discontinued Pipeline Products 349

Discontinued Pipeline Product Profiles 354

Pfizer Inc.-Company Statement 379

Pfizer Inc.-Locations And Subsidiaries 380

Head Office 380

Other Locations & Subsidiaries 380

Appendix 403

Methodology 403

Coverage 403

Secondary Research 403

Primary Research 403

Expert Panel Validation 403

Contact Us 403

Disclaimer 404

List of Figures

Pfizer Inc.-Pipeline by Top 10 Indication, 2016 25

Pfizer Inc.-Pipeline by Stage of Development, 2016 36

Pfizer Inc.-Monotherapy Products in Pipeline, 2016 37

Pfizer Inc.-Combination Treatment Modalities in Pipeline, 2016 38

Pfizer Inc.-Partnered Products in Pipeline, 2016 39

Pfizer Inc.-Out-Licensed Products in Pipeline, 2016 42

Pfizer Inc.-Pipeline by Top 10 Target, 2016 258

Pfizer Inc.-Pipeline by Route of Administration, 2016 267

Pfizer Inc.-Pipeline by Top 10 Molecule Type, 2016 268

Pfizer Inc.-Pipeline Products by Top 10 Mechanism of Action, 2016 269

List of Tables

Pfizer Inc., Key Information 23

Pfizer Inc., Key Facts 23

Pfizer Inc.-Pipeline by Indication, 2016 25

Pfizer Inc.-Pipeline by Stage of Development, 2016 36

Pfizer Inc.-Monotherapy Products in Pipeline, 2016 37

Pfizer Inc.-Combination Treatment Modalities in Pipeline, 2016 38

Pfizer Inc.-Partnered Products in Pipeline, 2016 39

Pfizer Inc.-Partnered Products/ Combination Treatment Modalities, 2016 40

Pfizer Inc.-Out-Licensed Products in Pipeline, 2016 42

Pfizer Inc.-Out-Licensed Products/ Combination Treatment Modalities, 2016 43

Pfizer Inc.-Pre-Registration, 2016 46

Pfizer Inc.-Filing rejected/Withdrawn, 2016 47

Pfizer Inc.-Phase III, 2016 48

Pfizer Inc.-Phase II, 2016 50

Pfizer Inc.-Phase I, 2016 52

Pfizer Inc.-Preclinical, 2016 54

Pfizer Inc.-Discovery, 2016 56

Pfizer Inc.-Pipeline by Target, 2016 258

Pfizer Inc.-Pipeline by Route of Administration, 2016 267

Pfizer Inc.-Pipeline by Molecule Type, 2016 268

Pfizer Inc.-Pipeline Products by Mechanism of Action, 2016 269

Pfizer Inc.-Recent Pipeline Updates, 2016 277

Pfizer Inc.-Dormant Developmental Projects,2016 357

Pfizer Inc.-Discontinued Pipeline Products, 2016 364

Pfizer Inc., Other Locations 395

Pfizer Inc., Subsidiaries 395

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Current R&D Portfolio of Pfizer Inc.; Pfizer Inc. - Key Therapeutics; Pfizer Inc. - Pipeline Overview and Promising Molecules; Pfizer Inc. - News; Pfizer Inc. - Latest Updates; Pfizer Inc. - Pipeline; Pfizer Inc. - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 96525
Site License
USD 3000 INR 193050
Corporate User License
USD 4500 INR 289575

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com